NEW YORK (GenomeWeb) – Goldfinch Bio announced its launch today with $55 million in Series A financing from Third Rock Ventures.

The firm said that it will use a patient database to collect and integrate genomic and phenotypic data to inform drug development. "Goldfinch will focus on actionable targets for intervention and develop precision therapies for genetically stratified patient groups," the firm noted in a statement, adding it would initially go after orphan indications with a known genetic component, such as focal segmental glomerulosclerosis and polycystic kidney disease.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.